BioAge Labs (NASDAQ:BIOA) Stock Moved Up to Hold by UBS Group

Key Points

• UBS Group upgraded BioAge Labs to a “Hold” rating, while the broader analyst consensus remains “Moderate Buy” with an average price target of $33.00.
• BioAge shares opened at $5.57, near their 52-week low of $5.04 and well below the 52-week high of $25.95; the stock’s 50-day and 200-day moving averages were $8.75 and $15.39, respectively.
• BioAge reported quarterly EPS of negative $0.58, beating estimates of negative $0.65, but remained deeply unprofitable with a negative net margin of 912.26%; major institutions including BlackRock and Jupiter Topco recently acquired positions.

BioAge Labs (NASDAQ:BIOA - Get Free Report) was upgraded by equities researchers at UBS Group to a "hold" rating in a report released on Sunday, Zacks reports.

A number of other equities analysts also recently commented on BIOA. BTIG Research reiterated a "buy" rating and set a $40.00 price objective on shares of BioAge Labs in a research report on Tuesday, September 8th. Roth Capital reissued a "buy" rating and issued a $25.00 price target on shares of BioAge Labs in a research note on Wednesday, September 9th. Needham & Company LLC decreased their price objective on BioAge Labs from $50.00 to $35.00 and set a "buy" rating on the stock in a report on Friday, July 31st. Weiss Ratings cut BioAge Labs from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Thursday, October 8th. Finally, Jefferies Financial Group set a $21.00 price target on shares of BioAge Labs in a research report on Friday, July 31st. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $33.00.

BioAge Labs Stock Performance

BioAge Labs stock opened at $5.57 on Friday. The business has a 50-day simple moving average of $8.75 and a two-hundred day simple moving average of $15.39. BioAge Labs has a 52-week low of $5.04 and a 52-week high of $25.95.

BioAge Labs (NASDAQ:BIOA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.65) by $0.07. BioAge Labs had a negative return on equity of 28.99% and a negative net margin of 912.26%. The company had revenue of $2.45 million during the quarter. On average, equities research analysts expect that BioAge Labs will post -2.45 EPS for the current year.

Institutional Investors Weigh In On BioAge Labs

Several large investors have recently made changes to their positions in BIOA. BlackRock Inc. acquired a new position in BioAge Labs during the 2nd quarter valued at $69,831,000. Jupiter Topco LLC acquired a new position in shares of BioAge Labs in the 2nd quarter worth approximately $52,597,000. Janus Henderson Group PLC raised its stake in BioAge Labs by 411.8% during the first quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company's stock worth $36,597,000 after acquiring an additional 1,685,063 shares in the last quarter. Walleye Capital LLC acquired a new stake in shares of BioAge Labs during the 2nd quarter worth about $8,686,000. Finally, Stempoint Capital LP acquired a new stake in shares of BioAge Labs during the first quarter worth approximately $5,923,000.

About BioAge Labs

BioAge Labs, Inc is a clinical-stage biotechnology company focused on developing medicines for diseases associated with aging. The company uses human longevity data, machine learning and biology research to identify therapeutic targets and develop treatments intended to address the biological drivers of aging and age-related decline.

BioAge's pipeline has included azelaprag, formerly known as BGE-105, an investigational small-molecule agonist of the apelin receptor. The company has evaluated azelaprag in clinical studies involving muscle function and has also investigated its potential use in combination with incretin-based medicines for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.